DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01580514

EMPIRE

CompletedPhase 4

Myocardial Protection of Exenatide in AMI

Cardioprotective Effects of Exenatide in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention ; Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

127

actual

Study population

Cardiovascular disease

Key I/E criterion

—

Primary endpoint

•Infarct size

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01580514
Org study IDKHMC-2012001

Timeline

Milestones

Study first posted2012-04-19estimated
Last update posted2012-04-19estimated
Study start2009-09 (month precision)
Primary completion2011-08actual (month precision)
Study completion2011-08actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Cardiovascular disease

Eligibility

Who can enroll

Minimum age20 Years
Maximum age79 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•age between 20 and 79 years
•patients presenting with first ST-segment elevation myocardial infarction
•Thrombolysis in Myocardial Infarction [TIMI] flow grade 0)

Exclusion criteria

•cardiac arrest
•ventricular fibrillation
•cardiogenic shock
•hemodynamic instability
•suspicious stent thrombosis
•left bundle branch block
•previous acute myocardial infarction
•previous coronary artery bypass operation
•significant valvular heart disease
•primary myocardial disease
•atrial fibrillation
•significant hepatic or renal dysfunction, hypoglycaemia,
•diabetic ketoacidosis
•active infection or chronic inflammatory disease
•malignancy
•women who were pregnant or who were of childbearing age

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes
1
Cardiometabolic biomarkers
1
Safety / tolerability / PK
1
Other (unclassified)
1

Cardiovascular outcomes

1 endpoint
Secondary/protocol endpoint

Clinical outcomes

Time frame:6 months after primary PCI

Expanded / custom MACE composite

composite event, event

componentsAll-cause death, Myocardial infarction (any), Coronary revascularization

Cardiometabolic biomarkers

1 endpoint
Primary/protocol endpoint/low confidence

Infarct size

Time frame:1 month

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Number of Participants with Adverse Events

Time frame:6 month after primary PCI

Treatment-emergent AEs (any)

event count, event

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

LV function

Time frame:at admission and 6 month after primary PCI

descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.